Short-course anti-CD154 induction followed by tacrolimus maintenance sustains pig-to-cynomolgus kidney xenograft function (TTS 2026) - Sep 17, 2026 - Abstract #P1.137; Pres time: Sep 21, 2026; 04:45 PM - 06:00 PM; Location: Hall 1-2; P1; "Background immunosuppression included rituximab, anti-thymocyte globulin, tacrolimus, mycophenolate mofetil, methylprednisolone, tocilizumab, etanercept, and crovalimab. In three of four recipients, xenograft function persisted after anti-CD154 discontinuation, suggesting that CD154 blockade may durably modulate early allo/xeno-immune priming beyond active dosing. These findings support further investigation of a CD154-based induction-to-tacrolimus maintenance strategy in non-thymokidney xenotransplantation and warrant controlled studies to define optimal duration, mechanisms, reproducibility, safety, and translational applicability in this setting."
Clinical • Nephrology • Transplant Rejection • CD40 • CD40LG • CD55 • ENTPD1
|
|
Sun Ae Hwang1; Sangil Min2; Kyoung Sik Park1; Hye Sun Shin1; Yu Rim Ahn1; Eun Yeol Yang1; Hyunil Kim3; Ik Jin Yun1
|